Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075) Juan C. Ramos, Joseph A. Sparano,

Slides:

Advertisements

Similar presentations

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

Advertisements

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma:

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.

CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.

Non-Hodgkin's lymphoma presenting as an isolated chest wall tumour

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Clinical Lymphoma, Myeloma and Leukemia

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( ) Sundar Jagannath, Rafat Abonour, Brian.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Focus on lymphomas Cancer Cell

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

Utility of Left Ventricular Ejection Fraction Measurements Before the Administration of Doxorubicin-Based Chemotherapy in Patients With Diffuse Large.

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan,

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML Benyam Muluneh, Kaitlyn Buhlinger,

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study Rena Buckstein,

Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy- Refractory Non-Hodgkin Lymphoma Robert M. Dean, Daniel H. Fowler,

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma Shumaila.

Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies

Patients With Celiac Disease and B-Cell Lymphoma Have a Better Prognosis Than Those With T-Cell Lymphoma Thorvardur R. Halfdanarson, Alberto Rubio–Tapia,

Clinical Lymphoma, Myeloma and Leukemia

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

Volume 381, Issue 9880, Pages (May 2013)

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Clinical Lymphoma, Myeloma and Leukemia

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas by Erin G. Reid, David Looney,

Volume 20, Issue 5, Pages (May 2019)

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Autologous Stem Cell Transplantation for POEMS Syndrome

Presentation transcript:

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075) Juan C. Ramos, Joseph A. Sparano, Michelle A. Rudek, Page C. Moore, Ethel Cesarman, Erin G. Reid, David Henry, Lee Ratner, David Aboulafia, Jeanette Y. Lee, Richard F. Ambinder, Ronald Mitsuyasu, Ariela Noy Clinical Lymphoma, Myeloma and Leukemia Volume 18, Issue 3, Pages 180-190.e2 (March 2018) DOI: 10.1016/j.clml.2018.01.004 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Consortium Diagram. *Histologic DLBCL Subtypes: Defined as Either GCB or ABC (Also Known as Post-GCB). By Immunophenotypic Criteria (GCB Type Was Considered When CD10 Was Expressed in > 30% of Cells, or if CD10−, BCL6+, and IRF4/MUM1−; All Others Were Considered to be ABC Type or Non-GC) Abbreviations: aa-IPI = age-adjusted International Prognostic Index; ABC = activated B–cell-like; DLBCL = diffuse large B-cell lymphoma; EPOCH = etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; GCB germinal center B–cell-like; MTD = maximum tolerated dosage; QD = daily. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 180-190.e2DOI: (10.1016/j.clml.2018.01.004) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Survival for the Study Population. A, One-year Event-free Survival for the Entire Study Population (n = 12). B, One-year Overall Survival for the Entire Study Population (n = 12) Clinical Lymphoma, Myeloma and Leukemia 2018 18, 180-190.e2DOI: (10.1016/j.clml.2018.01.004) Copyright © 2018 The Authors Terms and Conditions